Witam,
Amerykańskie badanie przeprowadzone w Narodowym Instytucie Zdrowia (NIH) ujawniło, że 32 miliony Amerykanów (ok. 14%) populacji ma we krwi autoprzeciwciała przeciwjądrowe (ANA), które atakują ich własne tkanki i wywołują choroby autoimmunologiczne (włączające autyzm). Inne badania wykazały, że szczepienia oraz pewne składniki szczepionek (szczególnie adjuwanty takie jak aluminium oraz tłuszcze, np. skwalen) indukują autoimmunizację i są przyczyną wielu chorób autoimmunologicznych.
Związki aluminium są dodawane do szczepionek od kilkudziesięciu lat i choć od dawna wiadomo, że są neurotoksyczne i immunotoksyczne, nikt dotąd nie przeprowadził wiarygodnych badań, które by wykazały, że podawane niemowlętom, starszym dzieciom i dorosłym w ilościach jakie stosuje się w szczepionkach są bezpieczne. Sytuacja jest analogiczna do stosowania rtęci w szczepionkach.
Wszystkie używane obecnie szczepionki zawierają aluminium jako adjuwant, gdyż bez niego nie wywoływałyby dostatecznej odpowiedzi immunologicznej. To znaczy, że nie ma szczepionek bezpiecznych, zwłaszcza dla małych dzieci. Niemowlęta mają niedojrzały układ odpornościowy, bo taki jest niezbędny dla prawidłowego rozwoju ich organizmów, ale ignoranccy i aroganccy producenci szczepionek uważają, że natura jest chorobą, którą koniecznie trzeba pokonać. Dodawanie różnych toksyn do szczepionek temu właśnie służy - zniszczeniu naturalnych barier komórkowych i uaktywneniu procesów patologicznych. Na konferencjach wakcynologów i producentów szczepionek, główne tematy dyskusji dotyczą tego jak za pomocą coraz bardziej szkodliwych adjuwantów sprawić, by noworodkom można było wstrzykiwać po kilkadziesiąt szczepionek na raz, zanim wyjdą ze szpitala, i żeby wytworzyły one odpowiedź immunologiczną, co bez tych adjuwantów się nie udaje. Zdrowie szczepionych dzieci nikogo nie obchodzi. Skutek jest taki, że współczesne silnie wyszczepione pokolenia dzieci w krajach rozwiniętych są najbardziej upośledzone fizycznie i neurologicznie w historii ludzkości i większość cierpi na jakieś choroby chroniczne. Nietrudno sobie wyobrazić opłakaną przyszłość tych dzieci i całych społeczeństw, w których większość obywateli będzie chronicznie chora. przeciwjądrowe
http://www.nih.gov/news/health/jan2012/niehs-13.htm
http://therefusers.com/category/refusers-newsroom/

http://lup.sagepub.com/content/21/2/118.full.pdf+html

1.
Lupus. 2012;21(2):223-30.
Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations.
Tomljenovic L, Shaw C.
Source
1Neural Dynamics Research Group, Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada.
Abstract
Immune challenges during early development, including those vaccine-induced, can lead to permanent detrimental alterations of the brain and immune function. Experimental evidence also shows that simultaneous administration of as little as two to three immune adjuvants can overcome genetic resistance to autoimmunity. In some developed countries, by the time children are 4 to 6 years old, they will have received a total of 126 antigenic compounds along with high amounts of aluminum (Al) adjuvants through routine vaccinations. According to the US Food and Drug Administration, safety assessments for vaccines have often not included appropriate toxicity studies because vaccines have not been viewed as inherently toxic. Taken together, these observations raise plausible concerns about the overall safety of current childhood vaccination programs. When assessing adjuvant toxicity in children, several key points ought to be considered: (i) infants and children should not be viewed as "small adults" with regard to toxicological risk as their unique physiology makes them much more vulnerable to toxic insults; (ii) in adult humans Al vaccine adjuvants have been linked to a variety of serious autoimmune and inflammatory conditions (i.e., "ASIA"), yet children are regularly exposed to much higher amounts of Al from vaccines than adults; (iii) it is often assumed that peripheral immune responses do not affect brain function. However, it is now clearly established that there is a bidirectional neuro-immune cross-talk that plays crucial roles in immunoregulation as well as brain function. In turn, perturbations of the neuro-immune axis have been demonstrated in many autoimmune diseases encompassed in "ASIA" and are thought to be driven by a hyperactive immune response; and (iv) the same components of the neuro-immune axis that play key roles in brain development and immune function are heavily targeted by Al adjuvants. In summary, research evidence shows that increasing concerns about current vaccination practices may indeed be warranted. Because children may be most at risk of vaccine-induced complications, a rigorous evaluation of the vaccine-related adverse health impacts in the pediatric population is urgently needed.
2.
Lupus. 2012;21(2):158-61.
Systemic lupus erythematosus following HPV immunization or infection?
Soldevilla H, Briones S, Navarra S.
Source
University of Santo Tomas, Manila, Philippines.
Abstract
Background and purpose: The link between autoimmunity and infectious agents has been strongly suggested by reports of lupus or lupus-like syndromes following immunization. This report describes three patients with either newly diagnosed systemic lupus erythematosus (SLE) or SLE flare, following vaccination for human papilloma virus (HPV). Case 1: A 17-year-old female completed two doses of HPV vaccine uneventfully. Two months later, she developed arthralgias with pruritic rashes on both lower extremities, later accompanied by livedo reticularis, bipedal edema with proteinuria, anemia, leucopenia, hypocomplementemia and high titers of anti-nuclear antibody (ANA) and anti-double-stranded DNA (anti-dsDNA). Kidney biopsy showed International Society of Nephrology/Renal Pathology Society Class III lupus nephritis. She was started on high dose steroids followed by pulse cyclophosphamide therapy protocol for lupus nephritis, and subsequently went into remission. Case 2: A 45-year-old housewife, previously managed for 11 years as having rheumatoid arthritis, had been in clinical remission for a year when she received two doses of HPV immunization. Four months later, she developed fever accompanied by arthritis, malar rash, oral ulcers, recurrent ascites with intestinal pseudo-obstruction, and behavioral changes. Cranial MRI showed vasculitic lesions on the frontal and parietal lobes. Laboratory tests showed anemia with leucopenia, hypocomplementemia, proteinuria, ANA positive at 1:320, and antibodies against dsDNA, Ro/SSA, La/SSB and histone. She improved following pulse methylprednisolone with subsequent oral prednisone combined with hydroxychloroquine. Case 3: A 58-year-old housewife diagnosed with SLE had been in clinical remission for 8 years when she received two doses of HPV immunization. Three months later, she was admitted to emergency because of a 1-week history of fever, malar rash, easy fatigability, cervical lymph nodes, gross hematuria and pallor. Laboratory exams showed severe anemia, thrombocytopenia, active urine sediments, and hypocomplementemia. Despite pulse steroid therapy, blood transfusions, intravenous immunoglobulin and aggressive resuscitative measures, she expired a day after hospital admission. Summary: These cases narrate instances of the onset or exacerbation of lupus following HPV immunization suggesting adjuvant-induced autoimmunity. On the other hand, there are reports of higher incidence of HPV infection in SLE, with the infection per se possibly contributing to disease activity. Thus, the benefit of HPV immunization may still outweigh the risk among these individuals.
3.
Lupus. 2012;21(2):146-52.
Autoimmunity following Hepatitis B vaccine as part of the spectrum of 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants' (ASIA): analysis of 93 cases.
Zafrir Y, Agmon-Levin N, Paz Z, Shilton T, Shoenfeld Y.
Source
1The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.
Abstract
Objectives: In this study we analyzed the clinical and demographic manifestations among patients diagnosed with immune/autoimmune-mediated diseases post-hepatitis B vaccination. We aimed to find common denominators for all patients, regardless of different diagnosed diseases, as well as the correlation to the criteria of Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants (ASIA). Patients and methods: We have retrospectively analyzed the medical records of 114 patients, from different centers in the USA, diagnosed with immune-mediated diseases following immunization with hepatitis-B vaccine (HBVv). All patients in this cohort sought legal consultation. Of these, 93/114 patients diagnosed with disease before applying for legal consultation were included in the study. All medical records were evaluated for demographics, medical history, number of vaccine doses, peri-immunization adverse events and clinical manifestations of diseases. In addition, available blood tests, imaging results, treatments and outcomes were recorded. Signs and symptoms of the different immune-mediated diseases were grouped according to the organ or system involved. ASIA criteria were applied to all patients. Results: The mean age of 93 patients was 26.5 ± 15 years; 69.2% were female and 21% were considered autoimmune susceptible. The mean latency period from the last dose of HBVv and onset of symptoms was 43.2 days. Of note, 47% of patients continued with the immunization program despite experiencing adverse events. Manifestations that were commonly reported included neuro-psychiatric (70%), fatigue (42%) mucocutaneous (30%), musculoskeletal (59%) and gastrointestinal (50%) complaints. Elevated titers of autoantibodies were documented in 80% of sera tested. In this cohort 80/93 patients (86%), comprising 57/59 (96%) adults and 23/34 (68%) children, fulfilled the required criteria for ASIA. Conclusions: Common clinical characteristics were observed among 93 patients diagnosed with immune-mediated conditions post-HBVv, suggesting a common denominator in these diseases. In addition, risk factors such as history of autoimmune diseases and the appearance of adverse event(s) during immunization may serve to predict the risk of post-immunization diseases. The ASIA criteria were found to be very useful among adults with post-vaccination events. The application of the ASIA criteria to pediatric populations requires further study.